Effects of lycopene supplementation in patients with localized prostate cancer

Experimental Biology and Medicine

Volumn 227, Issue 10, 2002, Pages 881-885

  Kucuk, Omer ^a,e   Sarkar, Fazlul H ^a   Djuric, Zora ^a   Sakr, Wael ^a   Pollak, Michael N ^b   Khachik, Fred ^c   Banerjee, Mousumi ^a   Bertram, John S ^d   Wood Jr , David P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Bldg 142   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e Division of Hematology and Oncology   (United States)

Author keywords

Chemoprevention; Connexin; Lycopene; Prostate cancer; Tomato carotenoids; Treatment

Indexed keywords

5 HYDROXYMETHYLDEOXYURIDINE; DNA; LYC O MATO; LYCOPENE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

APOPTOSIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; EATING HABIT; FOOD INTAKE; HUMAN; MALE; NUTRIENT; OXIDATION; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PROSTATE CARCINOMA; PROSTATECTOMY; RISK FACTOR; SURGICAL TECHNIQUE; TOMATO; TUMOR VOLUME; WESTERN BLOTTING;

CAESALPINIA CILIATA; LYCOPERSICON ESCULENTUM;

EID: 0036847259     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222701007     Document Type: Conference Paper

References (34)

1. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87:1767-1776, 1995.
2. Bertram JS. Carotenoids and gene regulation. Nutr Rev 57:182-191, 1999.
3. Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33:105-112, 1999.
4. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 24:257-266, 1995.
5. Park CK, Ishimi Y, Ohmura M, Yamaguchi M. Ikegami S. Vitamin A and carotenoids stimulate differentiation of mouse osteoblastic cells. J Nutr Sci Vitaminol 43:281-296, 1997.
6. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36:101-111, 2000.
7. Zhang L.-X, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: Relationship to their cancer chemopreventive action. Carcinogenesis 12:2109-2114, 1991.
8. Bertram JS, Pung A, Churley M, Kappock TJ IV, Wilkins LR, Cooney RV. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 12:671-678, 1991.
9. Zhang L-X, Cooney RV, Bertram JS. Carotenoids up-regulate connexin43 gene expression independent of their pro-vitamin A or antioxidant properties. Cancer Res 52:5707-5712, 1992.
10. Hotz-Wagenblatt A, Shalloway D. Gap junctional communication and neoplastic transformation. Crit Rev Oncogenesis 4:541-558, 1993.
11. Bertram JS, Bortkiewicz H. Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. Am J Clin Nutr 62(Suppl 6):1327s-1336s, 1995.
12. Riso P, Pinder A, Santangelo A, Porrini M. Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? Am J Clin Nutr 69:712-718, 1999.
13. Rao AV, Fleshner N, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: A case-control study. Nutr Cancer 33:159-164, 1999.
14. Mehta PP, Bertram JS, Loewenstein WR. Growth inhibition of transformed cells correlates with their junctional communication with normal cells. Cell 44:187-196, 1986.
15. Tsai H, Werber J, Davia MO, Edelman M, Tanaka KE, Melman A, Christ GJ, Geliebter J. Reduced connexin 43 expression in high grade, human prostatic adenocarcinoma cells. Biochem Biophys Res Commun 22:64-69, 1996.
16. Mehta PP, Lokeshwar BL, Schiller PC, Bendix MV, Ostenson RC, Howard GA, Roos BA. Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol Carcinog 15:18-32, 1996.
17. Mehta P, Perez-Stable C, Nadji M, Mian M, Asotra K, Roos BA. Suppression of human prostate cancer cell growth by forced expression of connexin genes. Develop Gene 24:91-110, 1999.
18. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta-1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188, 1997.
19. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Hormone Metab Res 26:81-84, 1994.
20. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401-407, 1991.
21. Chan JM, Stampfer MJ, Giovanucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 279:563-566, 1998.
22. Giovannucci E. Insulin-like growth factor-1 and binding protein-3 and risk of cancer. Horm Res 51(Suppl 3):34-41, 1999.
23. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor-1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118, 1997.
24. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor-I and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998.
25. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Met Rev 17:383-390, 1998-99.
26. Kucuk O, Sarkar F, Sakr W, Djuric Z, Khachik F, Pollak M, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10:861-868, 2001.
27. Sakr WA. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol 35:474-478, 1999.
28. Hossain MZ, Bertram JS. Retinoids suppress proliferation, induce cell spreading, and up-regulate connexin43 expression only in postconfluent 10T1/2 cells: Implications for the role of gap junctional communication. Cell Growth Differ 5:1253-1261, 1994.
29. Rao AV, Agarwal S. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. Nutr Cancer 31:199-203, 1998.
30. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein induced upregulation of p21, down regulation of cyclin B and induction of apoptosis in prostate cancer cells. Nutr Cancer 32:123-131, 1998.
31. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kB activation in prostate cancer cells. Nutr Cancer 35:167-174, 1999.
32. Hussain M, Sarkar FH, Djuric Z, Pollak MN, Banerjee M, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. J Nutr 132:575S-576S, 2002.
33. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-446, 1998.
34. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81:730-734, 1998.